Efficacy of Zoledronic Acid Combined with Calcium Carbonate D3 in the Treatment of Diabetic Osteoporosis and its Effects on Bone Mineral Density and Bone Metabolism Indexes
REN Hua, ZHANG Zhiliang, CAI Wei, et al
Luwan Branch, Ruijin Hospital, Medical School of Shanghai Jiaotong University, Shanghai 200020, China
Abstract：Objective: To investigate the efficacy of zoledronic acid combined with calcium carbonate D3 in the treatment of diabetic osteoporosis (DOP) and its effects on bone mineral density and bone metabolism indexes. Methods: 110 patients with DOP admitted to our hospital from September 2015 to May 2018 were selected and randomly group. 55 patients in control group were treated with Caltrate D3, and 55 patients in experimental group were given zoledronic acid combined with calcium carbonate D3. The clinical efficacy, bone mineral density, bone metabolism indexes, pain, incidence rate of complications and inflammatory factors were analyzed in the two groups. Results: After treatment, the total effective rate in experimental group (94.54%) was significantly higher than that in control group (80.00%) (P<0.05). After treatment, the bone mineral density values of lumbar vertebrae L1~4, femoral neck, femoral trochanter and Wards triangle region in the two groups were significantly increased compared with those before treatment (P<0.05), and the increases in experimental group were greater than those in control group (P<0.05). There were no significant differences in the levels of bone metabolism indexes of serum phosphorus and serum calcium between the two groups before and after treatment (P>0.05). After treatment, the levels of bone metabolism indexes of bone alkaline phosphatase (BALP), bone gla protein (BGP) and β-collagen fragment (β-CTX) and pain visual analogue scale (VAS) score in the two groups were decreased compared with those before treatment (P<0.05), and the decreases in experimental group were greater than those in control group (P<0.05). During treatment, there was not statistically significant difference between the two groups in the incidence rate of complications (P>0.05). After treatment, the levels of interleukin (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in the two groups were significantly decreased compared with those before treatment, and the decreases in experimental group were greater than those in control group (P<0.05). Conclusion: Zoledronic acid combined with calcium carbonate D3 in the treatment of DOP can increase bone mineral density, inhibit bone resorption, promote bone formation and reduce body inflammation, and is safe and effective.
任华, 张之梁, 蔡伟, 黄晓怡, 庞小芬. 唑来膦酸联合碳酸钙D3治疗糖尿病性骨质疏松症的疗效及其对患者骨密度和骨代谢指标的影响[J]. 河北医学, 2020, 26(1): 45-49.
REN Hua, ZHANG Zhiliang, CAI Wei, et al. Efficacy of Zoledronic Acid Combined with Calcium Carbonate D3 in the Treatment of Diabetic Osteoporosis and its Effects on Bone Mineral Density and Bone Metabolism Indexes. HeBei Med, 2020, 26(1): 45-49.
2020, Vol. 26 
冀公网安备13080202000677号